- Global Pharma News & Resources

ZGNX CLASS ACTION ALERT: Hagens Berman Alerts Zogenix (ZGNX) Investors to Securities Class Action, Encourages Investors to Contact the Firm

SAN FRANCISCO, April 16, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Zogenix, Inc. (NASDAQ: ZGNX) to the securities class action pending in the United States District Court for the Northern District of California and to the June 11, 2019 Lead Plaintiff deadline.  If you purchased or otherwise acquired Zogenix securities between February 6, 2019 and April 8, 2019 and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information about the case or to inquire about serving as Lead Plaintiff click

or contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing

According to the complaint, Defendants misled investors about Zogenix's much-anticipated New Drug Application ("NDA") for FINTEPLA┬«.  More specifically, according to the complaint, the NDA (1) contained inadequate non-clinical data and an incorrect version of a clinical dataset, and (2) consequently the NDA was unlikely to gain approval by the U.S. Food & Drug Administration ("FDA").

When, on April 8, 2019 Defendants announced the regulator determined that the NDA was not sufficiently complete to permit a substantive review, the price of Zogenix shares fell sharply lower on April 9, 2019.

"We're focused on investors' losses, whether Defendants knew that the NDA they submitted on February 5 was not sufficiently complete to permit the FDA to conduct a substantive review, and the extent to which investors may have been misled," said Hagens Berman partner Reed Kathrein.

Whistleblowers:  Persons with non-public information regarding Zogenix should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email

About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 78 attorneys in 9 offices across the country.  The Firm represents investors, whistleblowers, workers and consumers in complex litigation.  More about the firm and its successes can be found at  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Reed Kathrein, 510-725-3000

View original content to download multimedia:

SOURCE Hagens Berman Sobol Shapiro LLP

ZGNX CLASS ACTION ALERT: Hagens Berman Alerts Zogenix (ZGNX) Investors to Securities Class Action, Encourages Investors to Contact the Firm

Editor Details

Last Updated: 17-Apr-2019